a study of jnj-79635322 in combination with daratumumab with or without lenalidomide or in combination with pomalidomide for multiple myeloma

Conditions: Multiple Myeloma

Summary: the primary purpose of this study for part 1 (dose escalation) is to identify the safe effective dose (recommended phase 2 doses \[rp2ds\]) and schedule for jnj-79635322 treatment regimen in combination with daratumumab with or without lenalidomide or with pomalidomide; and for part 2 (dose expansion) is to further characterize the safety and tolerability of jnj-79635322 combination treatment regimens at selected rp2d(s).


Eligibility criteria:
inclusion criteria: * have documented initial diagnosis of multiple myeloma according to imwg diagnostic criteria * meet treatment regimen-specific requirements as follows: treatment regimen a (jnj-79635322+daratumumab):treatment regimen a1: have been treated with 1 to 3 prior lines of therapy, including a proteasome inhibitor (pi) and an inhibitor, immunomodulatory drug (imid) therapy for the treatment of multiple myeloma (mm); treatment regimen a2: newly diagnosed mm naïve to multiple myeloma (or other related plasma cell neoplasm)-directed treatments; treatment regimen b (jnj-79635322+pomalidomide): have received greater than or equal to (\>=) 1 prior line of therapy, including a pi and lenalidomide, and are lenalidomide refractory or \>=2 prior lines of therapy, including a pi and lenalidomide; treatment regimens c, d, and e: newly diagnosed mm naïve to multiple myeloma (or other related plasma cell neoplasm)-directed treatments * have a weight \>=40 kilograms * must have an eastern cooperative oncology group status of 0 or 2 * have measurable disease at screening as defined by at least 1 of the following: a) serum monoclonal protein (m-protein) level \>= 0.5 gram per deciliter (g/dl); or b) urine m-protein level \>=200 milligram (mg)/24 hours; or c) light chain multiple myeloma: serum immunoglobulin (ig) free light chain (flc) \>= 10 mg/dl and abnormal serum ig kappa lambda flc ratio. d) for participants without measurable disease in the serum, urine, or involved flc: presence of 1 or more focus of extramedullary disease which meets the following criteria: extramedullary plasmacytoma not contiguous with a bone lesion, at least 1 lesion \>=2 centimeter (cm) (at its greatest dimension) diameter on whole body positron emission tomography-computed tomography (or whole-body magnetic resonance imaging approved by sponsor), and not previously radiated exclusion criteria: * any serious underlying medical conditions, such as: a) evidence of active viral, bacterial, or systemic fungal infection requiring ongoing antiviral, antibacterial, or antifungal treatment. b) active autoimmune disease requiring systemic immunosuppressive therapy within 6 months before start of study treatment. c) cardiac conditions (myocardial infarction, unstable angina, or coronary artery bypass graft \<=6 months prior to enrollment; new york heart association stage iii or iv congestive heart failure et cetera) * prior antitumor therapy as follows, in the specified time frame prior to the first dose of study treatment: a) targeted therapy, epigenetic therapy, monoclonal antibody (mab) treatment, or treatment with an investigational drug or an invasive investigational medical device within 21 days or 5 half-lives, whichever is less. b) gene-modified adoptive cell therapy (example, chimeric antigen receptor \[car\] modified t cells, natural killer cells) within 90 days. c) prior anti-cd38 directed therapy within 90 days (for treatment regimen a only; within 21 days for treatment regimen b). d) conventional chemotherapy within 21 days. e) pi therapy within 14 days. f) immunomodulatory agent therapy within 7 days. g) radiotherapy within 14 days * stem cell transplantation: a) allogeneic stem cell transplant within 6 months before the first dose of study treatment. b) received an autologous stem cell transplant less than or equal to (\<=)12 weeks before the first dose of study treatment * nonhematologic toxicity from prior anticancer therapy that has not resolved to baseline level or to grade \<=1 (except alopecia, tissue post-rt fibrosis \[any grade\] or peripheral neuropathy grade \<=3) * prior treatment with cd3-redirecting therapy * the following medical conditions: pulmonary compromise requiring supplemental oxygen use to maintain adequate oxygenation, human immunodeficiency (hiv) infection, active hepatitis b or c infection, stroke or seizure within 6 months prior to first dose of study treatment